Literature DB >> 26203498

Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.

Anthony P Turel1, Keun Hee Oh, Ian S Zagon, Patricia J McLaughlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26203498     DOI： 10.1097/JCP.0000000000000373

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  7 in total

1.  Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Michael D Ludwig; Ian S Zagon; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-07

2.  Selective opioid growth factor receptor antagonists based on a stilbene isostere.

Authors:  David P Stockdale; Michelle B Titunick; Jessica M Biegler; Jessie L Reed; Alyssa M Hartung; David F Wiemer; Patricia J McLaughlin; Jeffrey D Neighbors
Journal:  Bioorg Med Chem       Date:  2017-06-27       Impact factor: 3.641

Review 3.  Intermittent blockade of OGFr and treatment of autoimmune disorders.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

4.  Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.

Authors:  Brendan O'Kelly; Louise Vidal; Tina McHugh; James Woo; Gordana Avramovic; John S Lambert
Journal:  Brain Behav Immun Health       Date:  2022-07-03

5.  Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.

Authors:  Michael D Ludwig; Ian S Zagon; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-02

6.  Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.

Authors:  Michael D Ludwig; Anthony P Turel; Ian S Zagon; Patricia J McLaughlin
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-09-29

7.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.

Authors:  Mitchell R K L Lie; Janine van der Giessen; Gwenny M Fuhler; Alison de Lima; Maikel P Peppelenbosch; Cokkie van der Ent; C Janneke van der Woude
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.